Discrimination of tetrahydroaminoacridine responders by a single dose pharmaco-EEG in patients with Alzheimer's disease

We report the results of our study suggesting that a single dose pharmaco-EEG may predict treatment response to tetrahydroaminoacridine (THA) in Alzheimer's disease (AD). 14 AD patients and 7 age-matched neurologically healthy controls were selected for the study. AD patients had 7 weeks' THA treatment. 6 patients were regarded as responders and 8 patients as nonresponders, respectively. AD patients as well as controls had a baseline EEG recording and next day another recording 90 minutes after a peroral single dose of 50 mg THA. The relative change from the baseline in the alpha-theta ratio was the most sensitive discriminator of responders and nonresponders (P = 0.004, ANOVA).

[1]  G. Chatellier,et al.  Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine. , 1990, BMJ.

[2]  L. Berg,et al.  Frequency analysis of the resting awake EEG in mild senile dementia of Alzheimer type. , 1983, Electroencephalography and clinical neurophysiology.

[3]  G. Buzsáki,et al.  Nucleus basalis and thalamic control of neocortical activity in the freely moving rat , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[4]  W. Osterrieder.  9‐Amino‐1,2,3,4‐tetrahydroacridine (THA) is a potent blocker of cardiac potassium channels , 1987, British journal of pharmacology.

[5]  J. Ashford,et al.  Advances in Alzheimer therapy: Cholinesterase inhibitors , 1989, Neurobiology of Aging.

[6]  A. Kling,et al.  Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. , 1986, The New England journal of medicine.

[7]  J. C. Stoof,et al.  Further analysis of the neuropharmacological profile of 9-amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease. , 1988, Life sciences.

[8]  E K Perry,et al.  Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. , 1978, British medical journal.

[9]  R. Bartus,et al.  The cholinergic hypothesis of geriatric memory dysfunction. , 1982, Science.

[10]  J. Overall,et al.  Long-term outpatient treatment of senile dementia with oral physostigmine. , 1988, The Journal of clinical psychiatry.

[11]  L. Fitten,et al.  Treatment of Alzheimer's disease with short- and long-term oral THA and lecithin: a double-blind study. , 1990, The American journal of psychiatry.

[12]  H. Soininen,et al.  Quantitative analysis of occipital EEG in different stages of Alzheimer's disease. , 1985, Electroencephalography and clinical neurophysiology.

[13]  H. Soininen,et al.  Longitudinal EEG spectral analysis in early stage of Alzheimer's disease. , 1989, Electroencephalography and clinical neurophysiology.

[14]  G. Blessed,et al.  NECROPSY EVIDENCE OF CENTRAL CHOLINERGIC DEFICITS IN SENILE DEMENTIA , 1977, The Lancet.

[15]  C. H. Vanderwolf.  Cerebral activity and behavior: control by central cholinergic and serotonergic systems. , 1988, International review of neurobiology.

[16]  P. Moriearty,et al.  Estimation of Plasma Tacrine Concentrations Using An In Vitro Cholinesterase Inhibition Assay , 1989, Alzheimer disease and associated disorders.

[17]  S. Gauthier,et al.  Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study. , 1990, The New England journal of medicine.

[18]  L. Powell,et al.  Enhanced drug metabolism in cigarette smokers. , 1976, British medical journal.

[19]  H Merskey,et al.  The electroencephalogram in Alzheimer-type dementia. A sequential study correlating the electroencephalogram with psychometric and quantitative pathologic data. , 1987, Archives of neurology.

[20]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[21]  R. Mayeux,et al.  Heterogeneity in dementia of the Alzheimer type , 1985, Neurology.

[22]  G. V. Van Hoesen,et al.  Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. , 1984, Science.

[23]  R. Mayeux,et al.  Long‐term administration of oral physostigmine in Alzheimer's disease , 1988, Neurology.

[24]  C. Cotman,et al.  Excitatory actions of tetrahydro-9-aminoacridine (THA) on hippocampal pyramidal neurons , 1987, Neuroscience Letters.

[25]  B. Pearce,et al.  Effects of tetrahydroaminoacridine on M1 and M2 muscarine receptors , 1988, Neuroscience Letters.

[26]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[27]  J. Sirviö,et al.  Relationship between the cortical choline acetyltransferase content and EEG delta-power , 1990, Neuroscience Research.

[28]  R. Jope,et al.  Biological and Neuropsychological Characterization of Physostigmine Responders and Nonresponders in Alzheimer's Disease , 1990, Journal of the American Geriatrics Society.

[29]  P. Riekkinen,et al.  Regulation of EEG delta activity by the cholinergic nucleus basalis , 1989 .

[30]  T. Gasser,et al.  Transformations towards the normal distribution of broad band spectral parameters of the EEG. , 1982, Electroencephalography and clinical neurophysiology.